Malignant mesothelioma

British Medical Bulletin

Volumn 93, Issue 1, 2010, Pages 105-123

  Rudd, R M ^a  

^a London Lung Cancer Group   (United Kingdom)

Author keywords

Asbestos; Chemotherapy; Epidemiology; Mesothelioma; Surgery

Indexed keywords

AMOSITE; AMPHIBOLE; ANGIOGENESIS INHIBITOR; ANGIOGENIC FACTOR; ASBESTOS FIBER; CARBOPLATIN; CHRYSOTILE; CISPLATIN; CROCIDOLITE; CYANOCOBALAMIN; ERLOTINIB; FLUORODEOXYGLUCOSE; FOLIC ACID; GEFITINIB; MEGAKARYOCYTE POTENTIATING FACTOR; MESOTHELIN; MITOMYCIN; NAVELBINE; OSTEOPONTIN; PEMETREXED; POLIOMYELITIS VACCINE; PROTEIN TYROSINE KINASE; RALTITREXED; SUNITINIB; TOBACCO SMOKE; TREMOLITE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VATALANIB; VINBLASTINE; ZEOLITE;

ASBESTOSIS; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; DIAGNOSTIC ACCURACY; DISEASE CLASSIFICATION; DISEASE MARKER; DNA DAMAGE; DRUG CHOICE; DRUG CONTAMINATION; DRUG EFFICACY; DRUG TREATMENT FAILURE; ENDEMIC DISEASE; EVIDENCE BASED PRACTICE; EXPOSURE; GENETIC IMMUNIZATION; GENETIC SUSCEPTIBILITY; GENOTOXICITY; HEREDITY; HISTOPATHOLOGY; HUMAN; KIDNEY CARCINOMA; LATENT PERIOD; LUNG ADENOCARCINOMA; LUNG BIOPSY; LUNG CANCER; LUNG RESECTION; MALIGNANT MESOTHELIOMA; MEDIASTINOSCOPY; MULTIMODALITY CANCER THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PLEURA EFFUSION; PLEURA PLAQUE; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RADIATION EXPOSURE; REVIEW; SEROLOGY; SIMIAN VIRUS 40; SMOKING; SURVIVAL TIME; THORAX RADIOGRAPHY; TREATMENT OUTCOME; TURKEY (REPUBLIC); VITAMIN SUPPLEMENTATION;

ASBESTOS; ASBESTOS, AMPHIBOLE; ASBESTOS, SERPENTINE; ENVIRONMENTAL EXPOSURE; HUMANS; MESOTHELIOMA; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; SIMIAN VIRUS 40;

EID: 77949350943     PISSN: 00071420     EISSN: 14718391     Source Type: Journal    
DOI: 10.1093/bmb/ldp047     Document Type: Review

References (45)

1. McDonald JC, McDonald AD (1996) The epidemiology of mesothelioma in historical context. Eur Respir J, 9, 1932-1942.
2. Rake C, Gilham C, Hatch J, Darnton A, Hodgson J, Peto J (2009) Occupational, domestic and environmental mesothelioma risks in the British population: a case-control study. Br J Cancer, 100, 1175-1183.
3. Peto J, Seidman H, Selikoff IJ (1982) Mesothelioma mortality in asbestos workers: implications for models of carcinogenesis and risk assessment. Br J Cancer, 45, 124-135.
4. Peto J, Decarli A, La Vecchia C, Levi F, Negri E (1999) The European mesothelioma epidemic. Br J Cancer, 79, 666-672.
5. Peto J, Rake C, Gilham C, Hatch J (2009) Occupational, Domestic and Environmental Mesothelioma Risks in Britain. Norwich: Health and Safety Executive.
6. Hodgson JT, McElvenny DM, Darnton AJ, Price MJ, Peto J (2005) The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050. Br J Cancer, 92, 587-593.
7. Newhouse ML, Thompson H (1965) Mesothelioma of the pleura and peritoneum following exposure to asbestos in the London area. Br J Ind Med, 22, 261-269.
8. Yates DH, Corrin B, Stidolph PN, Browne K (1997) Malignant mesothelioma in south east England: clinicopathological experience of 272 cases [published erratum appears in Thorax 1997, 52, 1018]. Thorax, 52, 507-512.
9. Hodgson JT, Darnton A (2000) The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure. Ann Occup Hyg, 44, 565-601.
10. McDonald JC, McDonald AD (1997) Chrysotile, tremolite and carcinogenicity. Ann Occup Hyg, 41, 699-705.
11. Roushdy-Hammady I, Siegel J, Emri S, Testa JR, Carbone M (2001) Genetic susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey. Lancet, 357, 444-445.
12. Price MJ, Darnton AJ, McElvenny et al. (2007) Simian virus 40 and mesothelioma in Great Britain. Occup Med (Lond), 57, 564-568.
13. Cavazza A, Travis LB, Travis WD, Wolfe JT 3rd, Foo ML, Gillespie DJ et al. (1996) Post-irradiation malignant mesothelioma. Cancer, 77, 1379-1385.
14. Doll R, Peto J (1985) Asbestos: Effects on Health of Exposure to Asbestos. London: HMSO.
15. Kamp DW (2009) Asbestos-induced lung diseases: an update. Transl Res, 153, 143-152.
16. Law MR, Hodson ME, Heard B (1982) Malignant mesothelioma of the pleura: relation between histological type and clinical behaviour. Thorax, 37, 810-815.
17. British Thoracic Society Standards of Care Committee (2007) Statement on malignant mesothelioma in the United Kingdom. Thorax, 62(Suppl. II).
18. De Vuyst P, Karjalainen A, Dumortier P et al. (1998) Guidelines for mineral fibre analyses in biological samples: report of the European Respiratory Society Working Group. Eur Respir J, 11, 1416-1426.
19. Leung AN, Muller NL, Miller RR (1990) CT in differential diagnosis of diffuse pleural disease. AJR, 154, 487-492.
20. Rusch V (1995) A proposed new international TNM staging system for malignant pleural mesothelioma. Chest, 108, 1122-1128.
21. Creaney J, Yeoman D, Demelker Y et al. (2008) Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol, 3, 851-857.
22. Steele JP, Klabatsa A, Fennell DA et al. (2005) Prognostic factors in mesothelioma. Lung Cancer, 49(Suppl. 1), S49-S52.
23. Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM et al. (1999) Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg, 117, 54-63.
24. Rusch VW, Venkatraman E (1996) The importance of surgical staging in the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc Surg, 111, 815-825.
25. Buduhan G, Menon S, Aye R, Louie B, Mehta V, Vallieres E (2009) Trimodality therapy for malignant pleural mesothelioma. Ann Thorac Surg, 88, 870-876.
26. Trousse DS, Avaro J-P, D'Journo XB et al. (2009) Is malignant mesothelioma a surgical disease ? A review of 83 consecutive extra-pleural pneumonectomies. Eur J Cardiothorac Surg, 36, 759-763.
27. Yan TD, Boyer M, Tin MM et al. (2009) Extrapleural pneumonectomy for malignant pleural mesothelioma: Outcomes of treatment and prognostic factors. J Thorac Cardiovasc Surg, 138, 619-624.
28. Treasure T, Waller D, Tan C et al. (2009) J Thorac Oncol. Epub ahead of print.
29. Grossebner MW, Arifi AA, Goddard M, Ritchie AJ (1999) Mesothelioma - VATS biopsy and lung mobilization improves diagnosis and palliation. Eur J Cardiothorac Surg, 16, 619-623.
30. Warren WH, Kalimi R, Khodadadian LM, Kim AW (2008) Management of malignant pleural effusions using the Pleur(x) catheter. Ann Thorac Surg, 85, 1049-1055.
31. Bissett D, Macbeth FR, Cram I (1991) The role of palliative radiotherapy in malignant mesothelioma. Clin Oncol (R Coll Radiol), 3, 315-317.
32. Lee C, Bayman N, Swindell R, Faivre-Finn C (2009) Prophylactic radiotherapy to intervention sites in mesothelioma: a systematic review and survey of UK practice. Lung Cancer, 66, 150-156.
33. Vogelzang NJ, Rusthoven JJ, Symanowski J et al. (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol, 21, 2636-2644.
34. Van Meerbeeck JP, Gaafar R, Manegold C et al. (2005) A randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an inter-group study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol, 23, 6881-6889.
35. Muers MF, Stephens RJ, Fisher P et al., on behalf of the MS01 Trial Management Group (2008) Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma: Results of the Medical Research Council/British Thoracic Society MS01 multi-centre randomised trial (ISRCTN54469112). Lancet, 371, 1685-1694.
36. Ceresoli GL, Zucali PA, Favaretto AG et al. (2006) Phase II Study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol, 24, 1443-1448.
37. Manegold C, Symanowski J, Gatzmeier U et al. (2005) Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol, 16, 923-927.
38. van den Bogaert DP, Pouw EM, van Wijhe G et al. (2006) Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma. J Thorac Oncol, 1, 25-30.
39. O'Brien MER, Watkins Ryan DC et al. (2006) A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial. Ann Oncol, 17, 270-275.
40. Jahan TM, Gu L, Wang X et al. (2007) Vatalanib (V) for patients with previously untreated advanced malignant mesothelioma (MM): a phase II study by the Cancer and Leukemia Group B (CALGB 30107). Proc Am Soc Clin Oncol, 25, 7081.
41. Nowak AK, Millward MJ, Francis R et al. (2008) Phase II study of sunitinib as second-line therapy in malignant pleural mesothelioma (MPM). Proc Am Soc Clin Oncol, 26, 8063.
42. Govindan R, Kratzke RA, Herndon JE et al. (2005) Gefitinib in patients with malignant mesothelioma: a phase II trial by the Cancer and Leukemia Group B. Clin Cancer Res, 11, 2300-2304.
43. Garland LL, Randkin C, Gandara DR et al. (2007) Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group study. J Clin Oncol, 25, 2406-2413.
44. Jackson MB, Pounder D, Price C, Matthews AW, Neville E (1999) Percutaneous cervical cordotomy for the control of pain in patients with pleural mesothelioma. Thorax, 54, 238-241.
45. Sebbag G, Yan H, Shmookler BM, Chang D, Sugarbaker PH (2000) Results of treatment of 33 patients with peritoneal mesothelioma. Br J Surg, 87, 1587-1593.